IS3703A7 - Aðferð til framleiðslu á efnasamsetningu til lækninga, sem er samverkandi og starfsmagnandi og aðferðir við notkun hennar - Google Patents

Aðferð til framleiðslu á efnasamsetningu til lækninga, sem er samverkandi og starfsmagnandi og aðferðir við notkun hennar

Info

Publication number
IS3703A7
IS3703A7 IS3703A IS3703A IS3703A7 IS 3703 A7 IS3703 A7 IS 3703A7 IS 3703 A IS3703 A IS 3703A IS 3703 A IS3703 A IS 3703A IS 3703 A7 IS3703 A7 IS 3703A7
Authority
IS
Iceland
Prior art keywords
cooperative
synergistic
preparation
methods
chemical composition
Prior art date
Application number
IS3703A
Other languages
English (en)
Other versions
IS2042B (is
Inventor
Andrea Fossa Anthony
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24080550&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS3703(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of IS3703A7 publication Critical patent/IS3703A7/is
Publication of IS2042B publication Critical patent/IS2042B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IS3703A 1990-05-11 1991-05-10 Aðferð til framleiðslu á efnasamsetningu til lækninga, sem er samverkandi og starfsmagnandi og aðferðir við notkun hennar IS2042B (is)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52236090A 1990-05-11 1990-05-11

Publications (2)

Publication Number Publication Date
IS3703A7 true IS3703A7 (is) 1991-11-12
IS2042B IS2042B (is) 2005-09-15

Family

ID=24080550

Family Applications (1)

Application Number Title Priority Date Filing Date
IS3703A IS2042B (is) 1990-05-11 1991-05-10 Aðferð til framleiðslu á efnasamsetningu til lækninga, sem er samverkandi og starfsmagnandi og aðferðir við notkun hennar

Country Status (33)

Country Link
US (2) US6716875B1 (is)
EP (1) EP0527879B1 (is)
JP (2) JPH0729938B2 (is)
KR (1) KR970005839B1 (is)
CN (7) CN101156949A (is)
AP (1) AP240A (is)
AT (1) ATE148632T1 (is)
AU (1) AU653724B2 (is)
BG (1) BG61831B1 (is)
BR (1) BR9106438A (is)
CA (1) CA2081564C (is)
DE (1) DE69124598T2 (is)
DK (1) DK0527879T3 (is)
EG (1) EG19648A (is)
ES (1) ES2097208T3 (is)
GR (1) GR3022997T3 (is)
GT (1) GT199100032A (is)
HU (1) HU227346B1 (is)
IE (1) IE911592A1 (is)
IL (1) IL98055A (is)
IS (1) IS2042B (is)
MA (1) MA22150A1 (is)
MY (1) MY114347A (is)
NO (1) NO924321L (is)
NZ (1) NZ238118A (is)
PE (1) PE30891A1 (is)
PT (1) PT97615B (is)
RO (1) RO115786B1 (is)
RU (1) RU2147875C1 (is)
TW (1) TW203553B (is)
WO (1) WO1991017771A1 (is)
YU (1) YU49094B (is)
ZA (1) ZA913539B (is)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0527879T3 (da) * 1990-05-11 1997-07-14 Pfizer Synergistiske terapeutiske præparater og fremgangsmåder.
EP0629408A1 (en) * 1993-06-16 1994-12-21 LABORATOIRES MERCK, SHARP & DOHME-CHIBRET Combination of angiotensin converting enzyme inhibitors and AII antagonists
DE4340437C1 (de) * 1993-11-27 1995-05-24 Karla Dr Lehmann Verwendung von Lithiumverbindungen zur Behandlung von Herzinsuffizienz einschließlich ihrer Folgeerkrankungen
CZ313897A3 (cs) * 1995-04-07 1998-01-14 Novartis Ag Farmaceutické kompozice obsahující benazepril nebo benazeprilát a valsartan
JPH11508894A (ja) * 1995-06-30 1999-08-03 メルク エンド カンパニー インコーポレーテッド Ａｃｅ阻害剤とａｉｉ拮抗薬を用いる腎疾患の治療方法
EP0914158B2 (en) * 1996-04-05 2006-01-25 Takeda Chemical Industries, Ltd. Pharmaceutical combination containing a compound having angiotensin ii antagonistic activity and a compound which increases the insulin-sensitivity
US6087386A (en) * 1996-06-24 2000-07-11 Merck & Co., Inc. Composition of enalapril and losartan
JP2000513356A (ja) * 1996-06-24 2000-10-10 メルク エンド カンパニー インコーポレーテッド エナラプリルとロサルタンの組成物
WO1999015643A2 (en) * 1997-09-25 1999-04-01 University Of Florida ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS TARGETED TO ANGIOTENSI N CONVERTING ENZYME mRNA AND METHODS OF USE
EP1047450B1 (en) * 1997-12-23 2002-10-02 Warner-Lambert Company Ace inhibitor-mmp inhibitor combinations
US6087343A (en) * 1998-09-14 2000-07-11 University Of Florida Antisense oligonucleotides targeted to β-1 adrenoceptor and methods of use
US6387894B1 (en) * 1999-06-11 2002-05-14 Pfizer Inc. Use of CRF antagonists and renin-angiotensin system inhibitors
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
CA2490811A1 (en) * 2002-06-28 2004-01-08 Novartis Ag Use of organic compounds
CA2811272C (en) 2003-04-08 2016-12-20 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
US20040265238A1 (en) 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
ES2384637T3 (es) * 2004-10-08 2012-07-10 Novartis Ag Uso de inhibidores de la renina para la prevención o el tratamiento de disfunción diastólica o insuficiencia cardiaca diastólica
ES2714198T3 (es) * 2005-03-07 2019-05-27 Univ Chicago Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
CL2007002689A1 (es) 2006-09-18 2008-04-18 Vitae Pharmaceuticals Inc Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
EP2565195B1 (en) 2007-03-29 2015-05-06 Wyeth LLC Peripheral opioid receptor and antagonists and uses thereof
JP2010522756A (ja) 2007-03-29 2010-07-08 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 結晶形およびその使用
PL2137191T3 (pl) 2007-03-29 2016-12-30 Antagoniści obwodowego receptora opioidowego i ich zastosowania
AU2008349873B2 (en) 2008-02-06 2014-02-13 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2'-bis-methylnaltrexone
CA2719134C (en) 2008-03-21 2015-06-30 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
AR077692A1 (es) 2009-08-06 2011-09-14 Vitae Pharmaceuticals Inc Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo
CN102423483A (zh) * 2011-11-24 2012-04-25 西北农林科技大学 一种复方雷米普利纳米乳抗高血压药物
CN114032273B (zh) * 2021-11-17 2024-02-02 山东省科学院生物研究所 一种多功能西洋参水解肽及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US324377A (en) * 1885-08-18 Roller-skate
US4046889A (en) * 1976-02-13 1977-09-06 E. R. Squibb & Sons, Inc. Azetidine-2-carboxylic acid derivatives
IL58849A (en) * 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
JPS5671074A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
US4749688A (en) 1986-06-20 1988-06-07 Schering Corporation Use of neutral metalloendopeptidase inhibitors in the treatment of hypertension
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
DE3633861A1 (de) * 1986-10-04 1988-04-07 Thomae Gmbh Dr K Neue imidazo-benzoxazinone, ihre herstellung und diese verbindungen enthaltende arzneimittel
US4814342A (en) 1986-10-31 1989-03-21 Pfizer Inc. Nor-statine and nor-cyclostatine polypeptides
US4895834A (en) * 1986-12-15 1990-01-23 Warner-Lambert Company Renin inhibitors III
US4874759A (en) * 1987-01-23 1989-10-17 Yoshitomi Pharmaceutical Industries, Ltd. 5-Hydroxyindole-3-carboxylic acid amide compounds, pharmaceutical compositions and use
US4962105A (en) 1987-10-19 1990-10-09 Ciba-Geigy Corporation Potentiation of antihypertensive effect of ace inhibitors
US4880804A (en) * 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
US5015651A (en) 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
CA1338238C (en) 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
IL91780A (en) 1988-10-04 1995-08-31 Abbott Lab History of the amine of the xenon-preventing xanine acid, the process for their preparation and the pharmaceutical preparations containing them
DK0527879T3 (da) * 1990-05-11 1997-07-14 Pfizer Synergistiske terapeutiske præparater og fremgangsmåder.

Also Published As

Publication number Publication date
US6900234B1 (en) 2005-05-31
ATE148632T1 (de) 1997-02-15
JPH0729938B2 (ja) 1995-04-05
PT97615B (pt) 1998-08-31
MA22150A1 (fr) 1991-12-31
YU81991A (sh) 1994-06-24
CN1824315B (zh) 2011-01-12
JPH05505618A (ja) 1993-08-19
WO1991017771A1 (en) 1991-11-28
BG61831B1 (bg) 1998-07-31
IL98055A (en) 1996-10-31
ZA913539B (en) 1992-12-30
CA2081564C (en) 1998-02-03
CN1824315A (zh) 2006-08-30
PT97615A (pt) 1992-03-31
YU49094B (sh) 2003-12-31
TW203553B (is) 1993-04-11
AU7859191A (en) 1991-12-10
ES2097208T3 (es) 1997-04-01
CA2081564A1 (en) 1991-11-12
CN1502370A (zh) 2004-06-09
NO924321L (no) 1993-01-08
DK0527879T3 (da) 1997-07-14
AP9100258A0 (en) 1991-07-31
GT199100032A (es) 1992-10-31
RU2147875C1 (ru) 2000-04-27
CN1056426A (zh) 1991-11-27
CN1307901A (zh) 2001-08-15
HU9203522D0 (en) 1993-01-28
NZ238118A (en) 1997-06-24
AP240A (en) 1993-02-18
HUT62804A (en) 1993-06-28
IE911592A1 (en) 1991-11-20
CN1879884A (zh) 2006-12-20
CN1065140C (zh) 2001-05-02
BG97068A (bg) 1993-12-24
CN101156949A (zh) 2008-04-09
EP0527879B1 (en) 1997-02-05
BR9106438A (pt) 1993-05-18
JP2635291B2 (ja) 1997-07-30
HU227346B1 (en) 2011-04-28
CN1915428A (zh) 2007-02-21
HK1094148A1 (en) 2007-03-23
JPH0748280A (ja) 1995-02-21
US6716875B1 (en) 2004-04-06
DE69124598D1 (de) 1997-03-20
EG19648A (en) 1995-09-30
CN100358578C (zh) 2008-01-02
IS2042B (is) 2005-09-15
GR3022997T3 (en) 1997-07-30
RO115786B1 (ro) 2000-06-30
KR970005839B1 (ko) 1997-04-21
IL98055A0 (en) 1992-06-21
NO924321D0 (no) 1992-11-10
DE69124598T2 (de) 1997-05-28
MY114347A (en) 2002-10-31
AU653724B2 (en) 1994-10-13
PE30891A1 (es) 1991-11-27
EP0527879A1 (en) 1993-02-24

Similar Documents

Publication Publication Date Title
IS3703A7 (is) Aðferð til framleiðslu á efnasamsetningu til lækninga, sem er samverkandi og starfsmagnandi og aðferðir við notkun hennar
IS3290A7 (is) Aðferð til framleiðslu á nýjum lyfjum sem eru afleiður katekóls og virka letjandi á katekól-O-metýltransferasa
EP0216413A3 (en) A process and an apparatus for the preparation of a disinfectant for water, such as drinking- or swimming-water
NO884135D0 (no) Vannopploeselig cellulosederivat, fremgangsmaate for dets fremstilling og anvendelse derav.
DK325982A (da) Findelt inhalationspraeparat og fremgangsmaade til fremstillingheraf
DK0489647T3 (da) N,O-sulfaterede heparosaner, fremgangsmåde til fremstilling heraf og lægemidler indeholdende disse forbindelser.
NO972475D0 (no) Ny antitrombotisk formulering, fremgangsmåte for dens fremstilling og anvendelse derav
FI923548A7 (fi) Vaahtoa muodostava koostumus farmaseuttiseen käyttöön, sen käyttö ja h oitomenetelmä
NO851643L (no) 1,4-dihydro-4-oksonafthyridin-derivater og salter derav, fremgangsmaate til fremstilling av forbindelsene og antibakterielle midler som innbefatter disse
DK0429760T3 (da) Fremgangsmåde til fremstilling af et aromatiseringsmiddel
NO875138D0 (no) Fremgangsmaate til fremstilling av et med teknetium 99m-markert organspesifikt stoff.
DE3660677D1 (en) Haloacetamide compounds, process for production thereof, and use thereof as herbicide
EP0475023A3 (en) Curable mixtures for the preparation of epoxy-networks, method for their preparation and their application
NO882562D0 (no) Nye 2-guanidino-tiazol-forbindelser fremgangsmaate for fremstilling derav og anvendelse derav.
IS4212A (is) Aðferð til framleiðslu á N-metýl-3-(1-metýl-4-píperidinýl)-1H-indól-5- etansúlfonamíð og lífeðlisfræðilega viðunandi söltum þess og lausnum þeirra
NO922385D0 (no) Mykt toerrfor, saerlig til bruk som avvenningsfor, og fremgangsmaate til fremstilling derav
ZA919373B (en) Process for the preparation of bromonitro-alcohols,dibromonitro-alcohols and blends thereof
DK635988A (da) 1,3-butandiolacetoacetat-derivater og anvendelse af 1,3-butandiolacetoacetat-forbindelser til fremstilling af farmaceutiske praeparater
DK336289D0 (da) Fremgangsmaade til fremstilling af morniflumat og analoge forbindelser
DK617684A (da) 1,3-dioxolanylderivater, fremgangsmaade til deres fremstilling, deres anvendelse og laegemidler indeholdende disse forbindelser
DE3462688D1 (en) 1,7-diphenyl-3-methylaza-7-cyano-8-methylnonane useful in combating diseases
NO881414D0 (no) Fremgangsmaate for behandling av spillvann og annet urent vann.
GR861529B (en) 1,4-dihydropyridine derivatives used for the treatment of cardiovascular diseases
IL100187A0 (en) Process for the preparation of bromonitro-alcohols,dibromonitro-alcohols and mixtures thereof
NO905543L (no) Fremgangsmaate for fremstilling og anvendelse av aminopyridinylmetanoler og aminometylpyridinaminer.